FOLIC ACID DEFICIENCY AND THE BACTERIOSTATIC MECHANISM OF SULFANILAMIDE DRUGS

Folic acid deficiency remains an important nutritional and clinical problem because folate is essential for one-carbon transfer reactions, DNA synthesis, and normal cell division. When folate stores are insufficient, rapidly proliferating tissues are affected first, leading to megaloblastic hematopoiesis, macrocytosis, mucosal changes, and in severe cases clinically significant anemia. The disorder is especially relevant in pregnancy, where inadequate folate availability increases the risk of neural tube defects in the developing embryo. Sulfanilamide drugs, in contrast, act as antibacterial agents by blocking bacterial folate biosynthesis. They are structural analogues of para-aminobenzoic acid and inhibit dihydropteroate synthase, a key enzyme absent in humans. By preventing formation of dihydropteroate and, downstream, tetrahydrofolate, these agents restrict the production of thymidylate, purines, and several other essential metabolites. This mechanism explains their bacteriostatic character: the drugs suppress microbial growth rather than directly lysing bacteria. The paper reviews the biochemical basis of folate deficiency, its major causes and manifestations, and the pharmacological logic underlying sulfanilamide action. It also highlights the clinical implications of folate depletion, drug resistance, and the importance of recognizing that human folate deficiency and bacterial folate inhibition are related only at the pathway level, not at the organism level.